• 1
    World Health Organization. Hepatitis C Fact sheet N°164. 2012 Available at Accessed 19 October 2012.
  • 2
    Negro F, Alberti A. The global health burden of hepatitis C virus infection. Liver Int 2011; 31 (Suppl. 2): 13.
  • 3
    Liu GG, DiBonaventura M, Yuan Y, et al. The burden of illness for patients with viral hepatitis C: evidence from a national survey in Japan. Value Health 2012; 15: S6571.
  • 4
    El-Kamary SS, Jhaveri R, Shardell MD. All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population. Clin Infect Dis 2011; 53: 1507.
  • 5
    Walter SR, Thein HH, Amin J, et al. Trends in mortality after diagnosis of hepatitis B or C infection: 1992–2006. J Hepatol 2011; 54: 87986.
  • 6
    Sherman KE. Advanced liver disease: what every hepatitis C virus treater should know. Top Antivir Med 2011; 19: 1215.
  • 7
    Walter SR, Thein HH, Gidding HF, et al. Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C. J Gastroenterol Hepatol 2011; 26: 175764.
  • 8
    O'Leary JG, Lepe R, Davis GL. Indications for liver transplantation. Gastroenterology 2008; 134: 176476.
  • 9
    Neff GW, Duncan CW, Schiff ER. The current economic burden of cirrhosis. Gastroenterol Hepatol (N Y) 2011; 7: 66171.
  • 10
    Yoshizawa H, Tanaka J, Miyakawa Y. National prevention of hepatocellular carcinoma in Japan based on epidemiology of hepatitis C virus infection in the general population. Intervirology 2006; 49: 717.
  • 11
    Chung H, Ueda T, Kudo M. Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology 2010; 53: 3943.
  • 12
    El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 126473.
  • 13
    Japan Society of Hepatology. Treatment guidelines for chronic hepatitis C. Hep Research 2013; 43: 134.
  • 14
    Kumada H, Toyota J, Okanoue T, et al. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012; 56: 7884.
  • 15
    Okanoue T, Hayashi N, Tsubouchi H, et al. Telaprevir in combination with peginterferon alfa 2B and ribavirin therapy for genotype 1 chronic HCV patients: phase 3 study in Japan. Hepatology 2011; 54(Suppl. 1): 985A [Abstract No. 1330].
  • 16
    Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 240516.
  • 17
    Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 241728.
  • 18
    Ozeki I, Akaike J, Karino Y, et al. Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients. J Gastroenterol 2011; 46: 92937.
  • 19
    INCIVEK™ (telaprevir) Highlights of US prescribing information. 2011 Available at Accessed 21 February 2012.
  • 20
    INCIVO™ (telaprevir) Summary of product characteristics. 2011 Available at Accessed 19 October 2012.
  • 21
    Seden K, Back D. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions. Curr Opin HIV AIDS 2011; 6: 51426.
  • 22
    Llinas-Brunet M, Bailey MD, Goudreau N, et al. Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335). J Med Chem 2010; 53: 646676.
  • 23
    Manns MP, Bourliere M, Benhamou Y, et al. Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol 2011; 54: 111422.
  • 24
    White PW, Llinas-Brunet M, Amad M, et al. Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. Antimicrob Agents Chemother 2010; 54: 46118.
  • 25
    Sulkowski MS, Asselah T, Lalezari J, et al. Faldaprevir combined with peginterferon alfa-2a and ribavirin in treatment-naive patients with chronic genotype-1 HCV: SILEN-C1 trial. Hepatology 2013; 57: 2143-54.
  • 26
    Sulkowski MS, Bourliere M, Bronowicki JP, et al. Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic HCV genotype-1 patients with prior nonresponse: SILEN-C2 trial. Hepatology 2013; 57: 2155-63.
  • 27
    Broom C. Design of first-administration studies in healthy man. In: O'Grady J, Linet OI (eds), Early Phase Drug Evaluation in Man, London: MacMillan Press; 1990. p20613.
  • 28
    Sane R, Podila L, Mathur A, et al. Mechanisms of isolated unconjugated hyperbilirubinemia induced by the HCV NS3/4A protease inhibitor BI201335. J Hepatol 2011; 54 (Suppl. 1): S488 [Abstract No. 1236].
  • 29
    Dieterich D, Asselah T, Guyader D, et al. SILEN-C3: treatment for 12 or 24 weeks with BI201335 combined with peginterferon alfa-2A and ribavirin (P.R) in treatment-naive patients with chronic genotype-1 HCV infection. Hepatology 2011; 54 (Suppl.): 378A [Abstract No. 36].